ATNX News and Press, Athenex Inc. From 07/11/22

Expected sale proceeds of approximately $19.0 million Company continues to monetize non-core assets to extend cash runway Proceeds from the deal will be used to pay down debt and fund operations BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Athenex, In...

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., Presi...

Buffalo, New York-based biotech Athenex (NASDAQ:ATNX) has agreed to sell the revenue generated from the U.S. and European royalty and milestone interests in skin care treatment Klisyri for Sagard Healthcare Partners and Oaktree Capital Management for $85M. Klisyri, also known as tirbanibulin ...

Company executes on strategy to extend cash runway by monetizing non-core assets Total transaction value of $85 million; at least $80 million to be used toward debt paydown and to fund operations BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ...

BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Darrel ...

Merck (MRK) has struck a collaboration and supply agreement with the cancer-focused biotech, Athenex (NASDAQ:ATNX) to jointly study its anti-PD-1 therapy Keytruda (pembrolizumab) with Athenex’s lead candidate Oraxol in patients with non-small cell lung cancer (NSCLC). Currently, Oraxol...

BUFFALO, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a clinical trial collaborat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Athenex, Inc. (ATNX) Q1 2022 Earnings Conference Call May 10, 2022, 08:00 AM ET Company Participants Caileigh Dougherty - Investor Relations Johnson Lau - Chief Executive Officer Daniel Lang - President, Athenex Cell Therapy Jeffrey Yordon - Chief Operating Officer Joe Annoni - Chief Financia...

Athenex press release (NASDAQ:ATNX): Q1 GAAP EPS of -$0.16 beats by $0.03. Revenue of $29.7M (-27.6% Y/Y) beats by $4.28M. FY22 Guidance: Athenex now expects product sales growth to be in the range of 20-25% over the prior year period, versus the prior range of 15-20% growth, year-over-year, ...